Home600664 • SHA
add
Harbin Pharmaceutical Group Co., Ltd.
Previous close
¥3.64
Year range
¥2.41 - ¥4.13
Market cap
9.49B CNY
Avg Volume
35.52M
P/E ratio
16.19
Dividend yield
-
Primary exchange
SHA
Market news
.DJI
0.37%
0.017%
Financials
Income Statement
Revenue
Net income
(CNY) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 4.00B | 6.05% |
Operating expense | 977.13M | 23.80% |
Net income | 166.64M | 175.81% |
Net profit margin | 4.17 | 160.62% |
Earnings per share | — | — |
EBITDA | 274.38M | 50.36% |
Effective tax rate | 22.99% | — |
Balance Sheet
Total assets
Total liabilities
(CNY) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 3.18B | 22.51% |
Total assets | 14.24B | 3.68% |
Total liabilities | 8.48B | -0.98% |
Total equity | 5.76B | — |
Shares outstanding | 2.52B | — |
Price to book | 1.82 | — |
Return on assets | 3.80% | — |
Return on capital | 7.00% | — |
Cash Flow
Net change in cash
(CNY) | Jun 2024info | Y/Y change |
---|---|---|
Net income | 166.64M | 175.81% |
Cash from operations | 344.42M | -1.27% |
Cash from investing | -15.62M | -70.10% |
Cash from financing | 15.19M | 115.53% |
Net change in cash | 344.23M | 40.80% |
Free cash flow | 377.94M | 6.99% |
About
Harbin Pharmaceutical Group Co., Ltd. is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. HPGC medication offerings include traditional Chinese medicine and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate.
The company owns both Renmintongtai, a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products. Wikipedia
Founded
1988
Website
Employees
9,853